Abiosciences is the US headquarters of Analytical Biosciences, a single cell genomics company focusing on accelerating the development of novel therapeutics. Its mission is to unlock the mechanism of diseases through the most advanced translational single cell platforms with the largest, high-resolution databases, and the most comprehensive commercial grade data analytics. Led by science and data, the company has been and will continue to generate new knowledge and compile/organize insights for the identification and validation of novel cellular targets and biomarkers, which ultimately lead to next generation breakthrough therapeutics and diagnostics.
View our webinars to learn about our latest ventures.
Visium Spatial Gene Expression for FFPE
Posted Mar 2022
In Vitro and In Silico Solutions
Posted Mar 2022
Breaking news and amazing progress in science and development of Abiosciences.
Dr. Dongxiao Zhang joins Analytical Biosciences as Chief Executive Officer of the U.S. Company
On May 1, 2022, Analytical Biosciences is pleased to announce that Dr. Dongxiao (Tony) Zhang, a veteran of the life sciences and pharmaceutical industry, joins as Chief Executive Officer of Abiosciences Inc., who will lead company’s single cell genomics partnership and services, sales and marketing, and corporate development.
Read moreDr. Su Zhang Joins Analytical BioSciences as Vice President of Global Strategy and Business Development
March 1, 2022, Analytical BioSciences (Abio) is pleased to announce that Dr. Su Zhang, a life sciences and pharmaceutical industry veteran, joins Abio as Vice President, Global Head of BD and Strategy. She will lead the pharmaceutical and biotechnology business partnerships and strategic development for the company.
Read moreDr. Xiaodong Andy Huang is promoted as the Chief Scientific Officer (CSO) of Analytical BioSciences
Dr. Xiaodong Andy Huang, Senior Vice President of Analytical BioSciences (Abio), is promoted to Chief Scientific Officer (CSO) to lead the company's overall drug R&D work, also will lead the Shanghai Discovery and Development Center to continuously improve the company's drug R&D capabilities and further accelerate the development of our innovative drug pipeline and discovery platforms.
Read more[Publication] Journal of Experimental Medicine | Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusion
Jan 21th, 2022, Beijing - Analytical BioSciences Ltd. (Abio), a leader in single cell genomics, is pleased to share that our client, Prof. Xinchun Chen’s group in Shenzhen University School of Medicine, has published a paper about tuberculous pleural effusion (TPE) in Journal of Experimental Medicine. Abio made great contributions to the single-cell data analysis part of the study.
Read moreWe are looking for best talents to join us in this transforming enterprise of biology and medicine. We encourage you to learn more about our company and explore our opportunities.